KR20070085232A - 혈관신생 치료방법 - Google Patents

혈관신생 치료방법 Download PDF

Info

Publication number
KR20070085232A
KR20070085232A KR1020077006403A KR20077006403A KR20070085232A KR 20070085232 A KR20070085232 A KR 20070085232A KR 1020077006403 A KR1020077006403 A KR 1020077006403A KR 20077006403 A KR20077006403 A KR 20077006403A KR 20070085232 A KR20070085232 A KR 20070085232A
Authority
KR
South Korea
Prior art keywords
angiogenesis
growth factor
vegf
vascular endothelial
endothelial growth
Prior art date
Application number
KR1020077006403A
Other languages
English (en)
Korean (ko)
Inventor
서브로토 채터지
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20070085232A publication Critical patent/KR20070085232A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Manufacturing & Machinery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Textile Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077006403A 2004-08-20 2005-08-19 혈관신생 치료방법 KR20070085232A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60301604P 2004-08-20 2004-08-20
US60/603,016 2004-08-20

Publications (1)

Publication Number Publication Date
KR20070085232A true KR20070085232A (ko) 2007-08-27

Family

ID=35968249

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077006403A KR20070085232A (ko) 2004-08-20 2005-08-19 혈관신생 치료방법

Country Status (9)

Country Link
US (1) US20090202439A1 (ja)
EP (1) EP1799258A4 (ja)
JP (1) JP2008510723A (ja)
KR (1) KR20070085232A (ja)
CN (1) CN101123879A (ja)
AU (1) AU2005277186A1 (ja)
CA (1) CA2581173A1 (ja)
RU (1) RU2007110847A (ja)
WO (1) WO2006023827A2 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053043A2 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
CA2593032C (en) 2004-12-27 2015-12-22 Silence Therapeutics Ag Coated lipid complexes and their use
BRPI0711626A2 (pt) * 2006-04-20 2011-12-06 Silence Therapeutics Ag meios para inibir expressão de cd31
WO2007134086A2 (en) 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
EP2167485B1 (en) 2007-05-31 2015-09-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
CA2701649C (en) 2007-10-05 2016-05-24 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
EP2320886B1 (en) 2008-07-28 2017-06-28 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CA2738768C (en) 2008-10-03 2017-10-31 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2012055814A1 (en) * 2010-10-25 2012-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv
US20170119683A1 (en) * 2014-04-28 2017-05-04 The Johns Hopkins University Biopolymer-encapsulated glycosyl transferase inhibitor compositions and methods for treating diabetes and cardiac indications
CN107502623B (zh) * 2016-06-13 2021-06-08 首都医科大学 递送VEGF-siRNA的纳米金刚石,其制备,活性和应用
WO2023019186A2 (en) * 2021-08-10 2023-02-16 The Johns Hopkins University Compositions and methods for treatment of cancer
CN115707472A (zh) * 2021-08-19 2023-02-21 中国科学院苏州纳米技术与纳米仿生研究所 C16 Laccer在制备修复脊髓损伤的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ATE358473T1 (de) * 1998-07-27 2007-04-15 Univ Johns Hopkins Diamino-propanol-verbindungen zur behandlung von ischaemien
EP1225910A2 (en) * 1999-11-02 2002-07-31 Genentech, Inc. MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
DE60329909D1 (de) * 2002-03-29 2009-12-17 Boston Scient Ltd Partikel für arzneistoffabgabe

Also Published As

Publication number Publication date
CN101123879A (zh) 2008-02-13
WO2006023827A3 (en) 2007-10-25
RU2007110847A (ru) 2008-09-27
AU2005277186A1 (en) 2006-03-02
EP1799258A2 (en) 2007-06-27
EP1799258A4 (en) 2009-07-22
US20090202439A1 (en) 2009-08-13
WO2006023827A2 (en) 2006-03-02
CA2581173A1 (en) 2006-03-02
JP2008510723A (ja) 2008-04-10

Similar Documents

Publication Publication Date Title
KR20070085232A (ko) 혈관신생 치료방법
JP6277127B2 (ja) インスリン様成長因子１による細胞の活性化を阻害するための方法
BR112020026386A2 (pt) Composições e métodos para modulação de fenótipos inflamatórios com monócitos e macrófagos e usos de imunoterapia dos mesmos
CN106573981A (zh) 利用抗cd40抗体的组合疗法
US20100074897A1 (en) Methods and Compositions related to HIF-1 alpha
CN111655247A (zh) 用lsd抑制剂与pd1结合拮抗剂的组合增强t细胞功能和治疗t细胞功能障碍病症
JP2016020351A (ja) 新規細胞上のＣｌｅｖｅｒ−１をモジュレートし得る医薬組成物
JP2013511543A (ja) 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
US20220073638A1 (en) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
WO2011038110A2 (en) Methods of treating metabolic disease
US20170202910A1 (en) Differentiation marker and differentiation control of eye cell
US10640768B2 (en) Method of treating pain with an antibody against netrin-4, UNC5B or neogenin
JP6198742B2 (ja) 肺高血圧症
TW202134278A (zh) 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞
CN110945128B (zh) 用于治疗肺纤维化的组合物和方法
JP7357347B2 (ja) 細胞外のＰＫＣδを標的とする肝癌細胞増殖抑制剤及びそれを含む新規肝癌治療薬
WO2009086952A2 (en) Compositions for the treatment of degenerative articular diseases
JP2021511837A (ja) Ｉｃａｍ−１マーカーおよびその応用
EP3258272B1 (en) Screening method for pain-relieving substances, and pharmaceutical composition for prevention or treatment of pain
US20110091485A1 (en) Modulation of cell junctions
EP4039273A1 (en) Monoclonal antibody or antibody fragment against canine cd20
WO2024024565A1 (ja) ニューロトリミンの機能阻害剤
WO2024119068A2 (en) S100a7 as a diagnostic marker and therapeutic target for disorders
KR20140144934A (ko) Ｃｔｈｒｃ１의 발현 및 활성 억제제를 유효성분으로 포함하는 췌장암 치료 및 전이억제용 조성물
US20080166339A1 (en) Inhibition of osteopontin for treatment of relapsing autoimmune disease

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application